Cassava Sciences Inc vs State Street PDR S&P Retail ETF — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while State Street PDR S&P Retail ETF trades at $88.96. The key difference: State Street PDR S&P Retail ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | XRT | |
|---|---|---|
Market Cap | $47.75M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $4.64 | $92.35 |
52-Week Low | $0.87 | $77.28 |
Enterprise Value | -$34.93M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.
The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.
XRT (SPDR S&P Retail ETF) trades at $88.83, down 1.94% on the day, with technical indicators showing a bullish overall signal despite recent weakness. The ETF maintains neutral oscillators but strong directional movement indicators. Recent retail sales data shows five consecutive months of consumer spending growth, though sentiment remains challenged by inflation pressures and energy costs. The ETF provides diversified exposure to the retail sector with upcoming dividend distribution scheduled for June 2026.
The retail sector faces mixed signals with sustained consumer spending but macroeconomic headwinds. XRT's technical setup suggests potential near-term support around $88-89 levels, while fundamental exposure to discretionary retail remains sensitive to consumer confidence and inflation trends. Key risks include deteriorating consumer sentiment and competitive pressures within the retail landscape.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →